Comparison of the effect of low-dose ropivacaine and lidocaine in intravenous regional anaesthesia - A randomised, double-blind clinical study


Bigat Z., Karsli B., Boztug N., Cete N., Ertok E.

CLINICAL DRUG INVESTIGATION, vol.25, no.3, pp.209-214, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 3
  • Publication Date: 2005
  • Doi Number: 10.2165/00044011-200525030-00007
  • Journal Name: CLINICAL DRUG INVESTIGATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.209-214
  • Akdeniz University Affiliated: Yes

Abstract

Abstract

The amide local anaesthetic ropivacaine is a pure S-enantiomer and is structurally related to bupivacaine. The duration of effect of ropivacaine is similar to that of bupivacaine, but ropivacaine has been shown to be associated with less depression of the cardiac conduction system.([1,2]) Intravenous ropivacaine, compared with bupivacaine and lidocaine, has demonstrated fewer cardiac and CNS adverse effects in several studies but has achieved similar levels of surgical anaesthesia. ([3-5]) Ropivacaine may serve as a local anaesthetic for intravenous regional anaesthesia (IVRA), providing prolonged and improved analgesia compared with lidocaine and with a lower toxicity profile when compared with bupivacaine. 

The purpose of this present study was to compare the anaesthetic and analgesic effectiveness of lidocame and ropivacaine for IVRA.

The amide local anaesthetic ropivacaine is a pure S-enantiomer and is structurally related to bupivacaine. The duration of effect of ropivacaine is similar to that of bupivacaine, but ropivacaine has been shown to be associated with less depression of the cardiac conduction system.([1,2]) Intravenous ropivacaine, compared with bupivacaine and lidocaine, has demonstrated fewer cardiac and CNS adverse effects in several studies but has achieved similar levels of surgical anaesthesia. ([3-5]) Ropivacaine may serve as a local anaesthetic for intravenous regional anaesthesia (IVRA), providing prolonged and improved analgesia compared with lidocaine and with a lower toxicity profile when compared with bupivacaine.